Ask what is BPC-157 and you'll get a tidy answer: a synthetic 15-amino-acid fragment, famously "stable in human gastric juice," therefore — the pitch goes — the rare peptide you can swallow. That last step is where most BPC-157 research summaries quietly break. Surviving stomach acid and reaching the bloodstream are two different measurements, and only one of them has actually been done. This piece looks at what the pharmacokinetic literature genuinely contains, what the widely-quoted oral bioavailability numbers trace back to, and why for readers asking "is BPC-157 legal in Australia", the route of administration changes nothing at all.

Stability Is Not Absorption

The stability claim is real and it is old. Work from the Croatian group that developed the peptide reported that synthetic BPC 157 remains intact in aspirated human gastric juice for more than 24 hours, a property attributed to its proline-rich sequence and the absence of the residues pepsin preferentially cleaves. That finding is repeated in essentially every review of the compound, including the Sikiric group's own 2024 overview of BPC 157's pleiotropic activity.

Oral drug delivery, though, is a three-step problem. A molecule has to (1) survive the stomach, (2) cross the intestinal epithelium into portal blood, and (3) survive first-pass metabolism in the gut wall and liver. Gastric stability answers step one only. For a 15-residue peptide with no obvious transporter, steps two and three are the hard ones — peptides of this size typically show oral bioavailability in the low single digits or below, and nothing about acid resistance predicts otherwise.

Critically, a compound can also act locally. Much of the original BPC 157 work was gastrointestinal: ulcers, colitis, anastomotic healing. A peptide that never leaves the gut lumen can still plausibly influence gut tissue. That is a defensible mechanism for a stomach model. It is not a mechanism for a swallowed capsule fixing an Achilles tendon.

The Only Real Pharmacokinetic Dataset — and What It Omits

The most rigorous PK work on this compound is a 2022 study in Frontiers in Pharmacology by Xu and colleagues, covering pharmacokinetics, distribution, metabolism and excretion in rats and beagle dogs. It used LC-MS/MS quantification and radiolabelled material, which puts it a tier above most of the literature. Its headline numbers:

  • Elimination half-life under 30 minutes, averaging roughly 15.2 minutes after a single intravenous dose in rats.
  • Absolute bioavailability after intramuscular injection of about 14–19% in rats and 45–51% in dogs.
  • Time to peak plasma concentration of around 3 minutes in rats and 6–9 minutes in dogs.
  • Excretion primarily via urine and bile; linear kinetics across the doses tested.

Two things follow. First, the 14–19% IM figure is itself a surprise to many readers — even injected into muscle, most of the dose in rats did not reach systemic circulation intact. Second, and more importantly for this discussion: the study's arms were intravenous and intramuscular. There is no oral arm. The best-characterised PK dataset on BPC-157 simply does not answer the oral question, and no peer-reviewed study in any species appears to have published a measured plasma concentration following a swallowed dose against a matched parenteral comparator.

That is not the same as saying oral doesn't work. It is saying the number does not exist.

Where "up to 90% oral bioavailability" Comes From

Search oral BPC-157 and you'll meet two figures: roughly 3% for the common acetate salt, and "up to 90%" for an arginate salt formulation. Both circulate as though they were measurements. Tracing them, they appear in vendor technical sheets, formulation patents and marketing pages — not in peer-reviewed pharmacokinetic literature. There is no published head-to-head study comparing oral arginate with oral acetate, and none measuring oral arginate against an injected reference in the same animals.

A patent claim is a legal document, not a bioequivalence study. Where a number has no primary source behind it, the honest description is "unmeasured", not "high".

Is BPC-157 Legal in Australia? Route Doesn't Change the Answer

This matters practically, because capsules are often marketed as a softer, more casual option. Australian scheduling doesn't work that way — it regulates the substance, not the delivery format.

BPC-157 has been listed in Schedule 4 (Prescription Only) with an additional Appendix D listing since 1 June 2024 under the Poisons Standard. Appendix D layers extra restrictions on top of ordinary prescription status. In practical terms, possessing BPC-157 in Australia without a valid authority is unlawful, and that applies identically to an oral capsule, a sublingual troche, a nasal spray or an injectable vial. The scheduling decision followed rising importation volumes, therapeutic claims in online marketing, and the absence of completed human trials — see the TGA's notice of final scheduling decisions.

BPC-157 is approved as a medicine nowhere in the world. It has been on the WADA Prohibited List since 2022 under S0 (non-approved substances), which is also route-agnostic — swallowing it is a doping violation on the same terms as injecting it. Australian athletes under a testing pool should treat oral products as identical risk.

Internationally, the US compounding picture shifted through 2026: BPC-157 left FDA's Category 2 list in April following a nomination withdrawal, and a July PCAC vote is advisory only. Neither development makes it lawfully compoundable, and neither has any bearing on Australian scheduling.

What Would Actually Close the Gap

The evidence ceiling here is not subtle. A 2025 systematic review in HSS Journal screened 544 articles from 1993 to 2024 and included 36 studies: 35 preclinical and one clinical. That single clinical entry was a retrospective series of 12 patients with chronic knee pain following intra-articular injection, in which 7 of 12 reported relief beyond six months — uncontrolled, unblinded, and tiny.

Three studies would change the conversation, in order:

  1. A basic oral PK study — plasma BPC-157 after a swallowed dose, with a parenteral arm in the same animals, published and peer-reviewed.
  2. A human PK study, since the rat-to-dog gap in IM bioavailability (14–19% vs 45–51%) shows species differences here are large.
  3. A randomised, placebo-controlled efficacy trial in a defined indication.

A note on step three: several 2026 posts claim the "first properly designed randomised controlled trial" of BPC-157 is now recruiting. Trial registry entries are self-submitted and not peer-reviewed, and at least some peptide listings circulating this year name sponsors that cannot be verified as real organisations. Before treating any registry record as evidence, check that the sponsor is a company or institution that demonstrably exists.

You can read the full compound profile at /peptides/bpc-157, compare it against other compounds in the /peptides section, or join the free updates list for plain-English coverage when primary research actually lands.

FAQ

Is BPC-157 legal in Australia?

No, not for general possession or use. BPC-157 has been Schedule 4 with an Appendix D listing since 1 June 2024, so possessing it without a valid authority is unlawful — and that applies to oral capsules exactly as it does to injectables.

Does oral BPC-157 actually get absorbed?

Nobody has published a measurement. BPC-157 is reported to survive human gastric juice for over 24 hours, but no peer-reviewed pharmacokinetic study in any species has reported plasma levels after a swallowed dose against a matched injected comparator.

What is BPC-157's half-life?

In the 2022 Frontiers in Pharmacology rat and dog study, the elimination half-life was under 30 minutes, averaging about 15.2 minutes after a single intravenous dose in rats. No human half-life has been published.

Are there human clinical trials of BPC-157?

Almost none. A 2025 HSS Journal systematic review included 36 studies, of which 35 were preclinical and one was a retrospective 12-patient case series. There are no published randomised, placebo-controlled efficacy trials.

Sources

This article is independent editorial information, not medical advice. BPC-157 is an investigational compound approved as a medicine in no country, is Schedule 4 with an Appendix D listing in Australia, and is prohibited in sport by WADA. We are not affiliated with any manufacturer or supplier.